<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85706">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922050</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1013</org_study_id>
    <nct_id>NCT01922050</nct_id>
  </id_info>
  <brief_title>A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis</brief_title>
  <official_title>Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1:

      To identify Maximum Tolerated Dose (MTD) levels of two formulations of  LEO 43204 after once
      daily treatment for two consecutive days

      Part 2:

      To evaluate efficacy of two formulations of  LEO 43204 in two doses after once daily
      treatment for two consecutive days compared to vehicle formulations
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part 1: Dose Limiting Toxicity based on Local Skin Responses (LSRs) up to and including Day 8</measure>
    <time_frame>8 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percent reduction in actinic keratosis (AK) counts from baseline to Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Complete clearance of AKs at week 8</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Partial clearance of AKs</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in AK count</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Part 1:  LEO 43204 Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1:  LEO 43204 Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 Formulation 1 Dose X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 Formulation 1 Dose Y</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 Formulation 2 Dose XX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 Formulation 2 Dose YY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2:  Placebo Formulation 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-Blind, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2:  Placebo Formulation 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-Blind, Once-Daily, 2-Day Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204 Formulation 1</intervention_name>
    <arm_group_label>Part 1:  LEO 43204 Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204 Formulation 2</intervention_name>
    <arm_group_label>Part 1:  LEO 43204 Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204 Formulation 1 Dose X</intervention_name>
    <arm_group_label>Part 2: LEO 43204 Formulation 1 Dose X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204 Formulation 1 Dose Y</intervention_name>
    <arm_group_label>Part 2: LEO 43204 Formulation 1 Dose Y</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204 Formulation 2 Dose XX</intervention_name>
    <arm_group_label>Part 2: LEO 43204 Formulation 2 Dose XX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204 Formulation 2 Dose YY</intervention_name>
    <arm_group_label>Part 2: LEO 43204 Formulation 2 Dose YY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Formulation 1</intervention_name>
    <arm_group_label>Part 2:  Placebo Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Formulation 2</intervention_name>
    <arm_group_label>Part 2:  Placebo Formulation 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Following verbal and written information about the trial, subject must provide
             informed consent documented by signing the Informed Consent Form (ICF) prior to any
             trial-related procedures.

          2. Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the
             face

          3. Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on either
             the face or within a contiguous area of approximately 250 cm2 (40 in2) on the chest

          4. Subject at least 18 years of age.

          5. Female subjects must be of either:

               1. Non-childbearing potential, i.e., have a confirmed clinical history of sterility
                  (e.g., the subject is without a uterus or have tubal ligation), or,

               2. Childbearing potential, provided there is a confirmed negative urine pregnancy
                  test prior to trial treatment.

          6. Female subjects of childbearing potential must use effective contraception throughout
             the study.

        Exclusion Criteria:

          1. Location of the treatment area within 5 cm (2 inches) of:

               1. an incompletely healed wound,

               2. a suspected basal or squamous cell carcinoma.

          2. Prior treatment with ingenol mebutate gel on the treatment area.

          3. Lesions in the treatment areas that have:

               1. atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous
                  horns) and/or

               2. recalcitrant disease (e.g., did not respond to cryotherapy on two previous
                  occasions).

          4. History or evidence of skin conditions other than the trial indication that would
             interfere with the evaluation of the trial medication (e.g., eczema, unstable
             psoriasis, xeroderma pigmentosum, Rosacea), at the investigator's discretion.

          5. Use of cosmetic or therapeutic products and procedures which could interfere with the
             assessments of the treatment areas.

          6. Any other disease or medical condition such as history or presence of cancer,
             cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,
             endocrine, immunological, or neurological disease or disorder, that, in the opinion
             of the investigator, makes the subject unsuitable to participate in the trial.

          7. Any abnormal laboratory or ECG findings that are clinically significant and would
             impact the safety of the subjects or the interpretation of the study results, as
             determined by the investigator.

          8. Anticipated need for hospitalisation or out-patient surgery during the first 15 days
             after the first trial medication application. Note that cosmetic/therapeutic
             procedures are not excluded if they fall outside of the criteria detailed in
             Prohibited Therapies or Medications.

          9. Known sensitivity or allergy to any of the ingredients in the LEO 43204.

         10. Presence of acute sunburn within the treatment areas.

         11. Current enrolment or participation in an investigational clinical trial within 30
             days of entry into this trial.

         12. Subjects previously randomised in the trial (Part 1 or 2).

         13. Female subjects who are breastfeeding.

         14. In the opinion of the investigator, the subject is unlikely to comply with the
             Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Goldenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine, Dermatology Faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aruna Sharma</last_name>
    <phone>905-747-2354</phone>
    <email>aruna.sharma@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Solomon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Nossa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth Tichy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
